NCT02266745View on ClinicalTrials.gov

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 1, 2024

Study Completion Date

April 1, 2025

Conditions
Advanced Solid TumorsCRPCmCRPCMetastatic Castrate-resistant Prostate CancerPT-112Prostatic NeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by Site
Interventions
DRUG

PT-112 Injection

Trial Locations (25)

10065

New York, New York

11215

Brooklyn, Brooklyn

19024

Seattle, Seattle

27705

Durham, Durham

32224

Jacksonville, Jacksonville

32806

Orlando, Orlando

46202

Indianapolis, Indianapolis

55426

Minneapolis, Minneapolis

55905

Rochester, Rochester

68130

Omaha, Omaha

77030

University of Texas MD Anderson Cancer Center, Houston

80045

Colorado, Aurora

85054

Arizona, Phoenix

85719

Tucson, Tucson

87190

Albuquerque, Albuquerque

91010

Duarte, Duarte

02215

Boston, Boston

Unknown

Besançon, Besançon

Bordeaux, Bordeaux

Caen, Caen

Clermont-Ferrand, Clermont-Ferrand

Marseille, Marseille

Nice, Nice

Paris, Paris

Rennes, Rennes

All Listed Sponsors
lead

Promontory Therapeutics Inc.

INDUSTRY